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Abstract
Hepcidin-25, the bioactive form of hepcidin, is a key regulator of iron homeostasis as it induces internalization and
degradation of ferroportin, a cellular iron exporter on enterocytes, macrophages and hepatocytes. Hepcidin levels are
increased in chronic hemodialysis (HD) patients, but as of yet, limited information on factors associated with hepcidin-25 in
these patients is available. In the current cross-sectional study, potential patient-, laboratory- and treatment-related
determinants of serum hepcidin-20 and -25, were assessed in a large cohort of stable, prevalent HD patients. Baseline data
from 405 patients (62% male; age 63.7613.9 [mean SD]) enrolled in the CONvective TRAnsport STudy (CONTRAST;
NCT00205556) were studied. Predialysis hepcidin concentrations were measured centrally with matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry. Patient-, laboratory- and treatment related characteristics were
entered in a backward multivariable linear regression model. Hepcidin-25 levels were independently and positively
associated with ferritin (p,0.001), hsCRP (p,0.001) and the presence of diabetes (p = 0.02) and inversely with the estimated
glomerular filtration rate (p = 0.01), absolute reticulocyte count (p = 0.02) and soluble transferrin receptor (p,0.001). Men
had lower hepcidin-25 levels as compared to women (p = 0.03). Hepcidin-25 was not associated with the maintenance dose
of erythropoiesis stimulating agents (ESA) or iron therapy. In conclusion, in the currently studied cohort of chronic HD
patients, hepcidin-25 was a marker for iron stores and erythropoiesis and was associated with inflammation. Furthermore,
hepcidin-25 levels were influenced by residual kidney function. Hepcidin-25 did not reflect ESA or iron dose in chronic stable
HD patients on maintenance therapy. These results suggest that hepcidin is involved in the pathophysiological pathway of
renal anemia and iron availability in these patients, but challenges its function as a clinical parameter for ESA resistance.
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Introduction
Hepcidin is a key regulator of iron homeostasis in humans. It
induces internalization and degradation of ferroportin, which is a
cellular iron exporter on enterocytes, macrophages and hepato-
cytes [1,2]. Hence, hepcidin reduces iron absorption from the gut
and iron release from reticuloendothelial and hepatocyte stores.
The bioactive form is hepcidin-25, a mainly protein-bound amino
acid of 2.8 kD, whereas hepcidin-20 and hepcidin-22 are its
isoforms with unknown biological function [2,3]. The expression
of hepcidin is regulated in response to iron administration,
erythropoietic demand, hypoxia and inflammatory signals [2,4].
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Hepcidin is excreted with the urine. In patients with chronic
kidney disease (CKD), serum levels of the active hepcidin-25 and
its isoforms are increased [5,6]. In patients with end stage renal
disease (ESRD) on dialysis, even higher levels of hepcidin have
been observed [5,6]. Hepcidin is the intermediary between
available iron stores on the one hand, and erythropoiesis on the
other hand. Furthermore, it has been suggested that hepcidin is an
important tool to predict the response to erythropoiesis stimulating
agents (ESA) [7,8,9]. Therefore, hepcidin might be useful to assess
the functional iron availability in patients with renal failure as high
levels might indicate a blockade of iron release from its stores [10].
In several studies, patient-, laboratory- and treatment charac-
teristics of CKD and ESRD patients have been related with
hepcidin levels. Many studies have shown a relation between
ferritin levels and hepcidin, both in CKD [5,6,9,11] and in
hemodialysis (HD) patients [5,12,13,14,15]. Furthermore, studies
in CKD and HD patients have shown associations with hepcidin
and various other parameters such as residual kidney function
(RKF) [6,11,16], ESA dose [11] and markers of inflammation
including C-reactive protein (CRP), tumor necrosis factor a (TNF-
a) and interleukin-6 (IL-6) [7,15]. In these studies, hepcidin has
been measured with different techniques, mainly competitive
immunoassays and mass spectrometry (MS) based methods,
impeding direct comparisons [3,17,18]. Furthermore, most studies
on hepcidin in HD patients included a limited number of patients,
precluding multivariate statistics.
In the current study, patient-, laboratory- and treatment
characteristics that are associated with hepcidin levels are
evaluated with a state-of-the-art hepcidin assay in a prospective
cohort of over 400 chronic HD patients, included in the
CONvective TRAnsport STudy (CONTRAST).
Materials and Methods
Patients and Study Design
Baseline data from patients enrolled in the CONTRAST study
(NCT00205556) were used. The rationale and the design of the
CONTRAST study have been described before [19]. In short,
prevalent HD patients were recruited from 2004 until 2010 and
randomized to either continue treatment with low flux HD, or
switch to treatment with post-dilution online hemodiafiltration,
both with ultrapure dialysate, with a variable follow up until
December 2010. Primary endpoint of the study is all cause
mortality [20], and anemia management is a secondary endpoint.
A total of 714 patients were recruited from 29 dialysis centers. In
the design phase of CONTRAST, a protocol for blood sampling
and storage was added, specifically for future studies on newly
identified markers that would become potentially relevant and of
interest. Hepcidin is an example of such a marker. In 17 of the 29
dialysis centers, in which blood sampling and storage was
logistically feasible, predialysis blood samples from participating
patients were drawn and stored at280uC. The selection of centers
participating in this sub-study was made prior to enrolment. The
present analyses were based on a subset of patients from the main
study, namely those participants (n = 405) from who additional
blood samples were collected.
Patients were eligible for inclusion in the main study if they were
treated two or three times per week with HD for at least two
months. Exclusion criteria were age below 18 years, treatment
with hemo(dia)filtration or high-flux HD in the six months prior to
randomization, a life expectancy less than three months due to
non-renal disease, participation in another clinical intervention
trial evaluating cardiovascular outcomes and severe incompliance
regarding frequency and/or duration of dialysis treatment.
The study was conducted in accordance with the Declaration of
Helsinki and was approved by a central medical ethics committee
and by all local medical ethics review boards. Written informed
consent was obtained from all patients prior to enrolment (File S1).
Patients provided informed consent for storage of blood samples
for later analysis.
Treatment Protocol
Included patients were stable for at least two months with a
minimum dialysis spKt/Vurea of 1.2 per treatment and they were
treated with either polysulfone (PS) or polyarylethersulfone (PAES)
low-flux dialyzers with a UF coefficient varying between 10 and
21 ml/mmHg/h and a surface area from 1.3 to 2.2 m2: F6HPS,
F7HPS, F8HPS and F10HPS (Fresenius Medical Care, Bad
Homburg, Germany) and Polyflux 14 L, 17 L and 21 L (Gambro
Corporation AB, Lund, Sweden). Dialysis was performed with
ultrapure dialysis fluids, containing less than 0.1 colony forming
units per mL and less than 0.03 endotoxin units per mL.
Routine patient care and prescription of medication was
practiced according to the opinion of the attending nephrologist
and based on the Quality of Care Guidelines of the Dutch
Federation of Nephrology. The Dutch Quality of Care Guideline
on anemia management was derived from the European Best
Practice Guidelines [21] and the KDOQI guidelines [22,23,24].
ESA and iron supplements were administered via the venous
bloodline at the end of a dialysis session. Decisions on dose
changes and the timing of these changes were made according to
the opinion of the treating nephrologist.
Laboratory Protocol
Predialysis blood samples were drawn and routine laboratory
assessments were analyzed in the local hospitals by standard
laboratory techniques. The total iron-binding capacity (TIBC) was
considered to represent serum transferrin level [25] and the
transferrin saturation ratio (TSAT) was either provided by the
local laboratory or calculated as serum iron divided by the TIBC.
Hepcidin, soluble transferrin receptor (sTfR), hsCRP and IL-6
measurements were preformed centrally. For this purpose,
predialysis blood samples were centrifuged at 1500 g and 4uC
for 10 minutes and stored at 280uC.
Serum hepcidin-20 and -25 measurements were centrally
performed by a validated combination of weak cation exchange
(WCX) bead-based hepcidin enrichment followed by time-of-flight
mass spectrometry (WCX-TOF-MS) [17]. For the quantification
of hepcidin in serum, an internal standard (synthetic hepcidin-24,
Peptide International Inc., Louisville, KY, USA) was used [26].
Peptide spectra were generated on a Microflex LT matrix-
enhanced laser desorption/ionisation (MALDI-) TOF-MS plat-
form (Bruker Daltonics GmbH, Bremen, Germany). Serum
hepcidin-20 and -25 concentrations were expressed as nmol/L
and the lower limit of detection of this method was 0.5 nmol/L.
For hepcidin-25, the intra-assay coefficients of variation (CV) were
3.7% at 7.9 nmol/L, 2.3% at 13.4 nmol/L, and 2.2% at
3.1 nmol/L. The inter-assay CV were 9.1% at 7.8 nmol/L and
3.9% at 12.9 nmol/L [17]. This method enables the specific
measurement of the hepcidin isoforms (hepcidin-25, hepcidin-22
and hepcidin-20) [17] and has been described before in CKD and
HD patients [5]. It is an update of a previous method performed
by the same laboratory [26,27]. sTfR (mg/L) was measured
immunonephelometrically on a BN II System (Dade Behring
Marburg GmbH, Marburg, Germany). hsCRP (mg/L) was
measured with a particle-enhanced immunoturbidimetric assay
on a Roche-Hitachi analyzer (Roche Diagnostics GmbH, Mann-
heim, Germany) with a lower quantification limit of 0.1 mg/L and
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an intra-assay variation of 1.9% at the level of 0.57 mg/L and
0.3% at the level of 3.00 mg/L. The inter-assay variation was
1.9% at the level of 0.67 mg/L and 1.2% at the level of 3.64 mg/
L. IL-6 (pg/mL) was measured with an immunometric assay
(Sanquin, Amsterdam, The Netherlands). The intra-assay varia-
tion was 12% at the level of 1 pg/mL and 8% at the level of 3 pg/
mL. The inter-assay variation was 19% at the level of 0.35 pg/mL
(which was the lower quantification limit) and 12% at the level of
2.3 pg/mL.
Data Collection
Data on demography, cause of renal failure, history of
cardiovascular disease (CVD), diabetes mellitus (DM), type of
vascular access, dialysis vintage and treatment parameters were
collected, as well as medication use. ESA was prescribed as
epoetin a or b (EprexH or NeorecormonH respectively, IU) or
darbepoetin a (AranespH, mg) and expressed as a dose per week.
To compare the different types of ESA, prescribed dosages were
converted to daily defined doses (DDD), using conversion
factors as provided by the World Health Organization (WHO)
Drug Classification (http://www.whocc.no/atc_ddd_index/).
For darbepoetin a (ATC code B03XA02), DDD is 4.5 mg and
for epoetin a and b (ATC code B03XA01), DDD is 1000 IU.
All patients on iron therapy used iron sucrose (VenoferH, mg/
week).
RKF was defined as a urine production of .100 mL/d. In
patients with RKF, the eGFR (estimated glomerular filtration rate)
was calculated as the mean of creatinine and urea clearance in a
24 h urine collection, adjusted for body surface area [28].
Table 1. Patient and treatment characteristics and laboratory
parameters.a
N=405
Patient characteristics
Male gender – no. (%) 252 (62)
Age (years) 63.7613.9
Caucasian race – no. (%) 333 (82)
Dialysis vintage (years) 1.8 (0.9–3.6)
Cause of renal failure - no. (%)
- vascular 131 (32)
- diabetes mellitus 63 (16)
- tubulointerstitial nephritis/glomerulo-
nephritis/multisystem disease
96 (24)
- cystic disease 28 (7)
- other/unknown 87 (21)
Diabetes mellitus – no. (%) 85 (21)
History of cardiovascular disease – no. (%) 177 (44)
Current smoker – no. (%) 81 (20)
Body weight (kg)b 71.7614.6
Systolic blood pressure (mmHg)c 142618
Diastolic blood pressure (mmHg)c 73611
BMI (kg/m2) 25.064.8
Residual diuresis – no. (%)d 230 (57)
eGFR (ml/min/1.73 m2)e 2.6 (1.2–5.1)
Treatment characteristics
Treatment frequency 3x/week – no. (%) 375 (93)
Treatment time (min) 227623
Bloodflow (mL/min) 298639
Dialysis access – no. (%)
- fistula 339 (84)
- graft 56 (14)
- central catheter 10 (2)
spKt/V (per dialysis) 1.3960.20
Dialyzer – no. (%)
- polysulfone 246 (61)
- polyarylethersulfone 147 (37)
- other 12 (3)
Prescription of ESA- no. (%) 364 (90)
Type of ESA – no. (%)
- darbepoetin a 254 (70
- epoetin a/b 110 (30)
ESA dose (DDD/week)f 8.9 (6.0–15.4)
Use of iron replacement therapy – no. (%) 300 (74)
Irondose (mg/week)g 100 (50–100)
Prescription of RAS inhibitors – no. (%) 215 (53)
Prescription of statin – no. (%) 203 (50)
Laboratory parameters
Hemoglobin (g/dL) 11.961.3
Hematocrit 0.3660.04
MCV (fl) 94.966.2
Reticulocytes (x109/L) 65.3630.5
Ferritin (ng/mL) 378 (211–631)
Table 1. Cont.
N=405
TSAT (%) 24.3612.4
sTfR (mg/L)h 1.58 (1.24–2.11)
Cholesterol (mg/dL) 143.1638.7
Albumin (g/dL) 3.660.5
hsCRP (mg/L) 3.95 (1.38–10.41)
Il-6 (pg/mL) 2.06 (1.21–3.82)
Hepcidin-20 (nM) 6.3 (3.9–9.3)
Hepcidin-25 (nM)i 13.8 (6.6–22.5)
aValues represent mean 6 SD, median (interquartile range) or proportion (%).
bWeight after dialysis (dry weight) defined as the mean of three consecutive
values.
cMean of pre- and post-dialysis blood pressure of three consecutive dialysis
sessions.
dDefined as .100 mL per day.
eeGFR (estimated glomerular filtration rate) calculated as mean of creatinine
and urea clearance in 24 h urine collection adjusted for body surface area,
exclusively in patients with residual diuresis.
fIn patients on ESA therapy.
gIn patients on iron therapy.
hReference value: 0.76–1.76 mg/L (Dade Behring Marburg GmbH, Marburg,
Germany).
iReference value (median [95% range]): men 65–69 years 5.3 (,0.05–13.9);
women 65–69 years 4.9 (,0.05–14.2) [29].
Conversion factors for units: hemoglobin in g/dL to mmol/L, x 0.62; cholesterol
in mg/dL to mmol/L, x 0.026; albumin in g/dL to g/L, x 10; no conversion
necessary for ferritin in ng/mL to mg/L.
BMI = body mass index; ESA = erythropoiesis stimulating agents; RAS = renin
angiotensin system; TSAT = transferrin saturation ratio; sTfR = soluble transferrin
receptor; PTH=parathyroid hormone; hsCRP = high sensitive c-reactive protein;
IL-6 = interleukin-6.
doi:10.1371/journal.pone.0039783.t001
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Statistical Analysis
Variables were reported as proportions or means 6 standard
deviation (SD), or medians with 25th–75th percentiles when
appropriate. The relation between hepcidin-20 and hepcidin-25
was evaluated with a Spearman’s correlation test. All patient
characteristics, laboratory parameters and treatment characteris-
tics listed in table 1, were considered as possible determinants of
hepcidin-25. First, relations between these determinants and
hepcidin-25 were studied using a backward multivariable linear
regression model with a p-value ,0.15 as a cut-off level.
Subsequently, the determinants that were related with Hepcidin-
25 (with a p-value ,0.15) were entered in a second multivariable
regression model. In this second regression model, a double sided
p-value ,0.05 was considered statistically significant. The natural
logarithm of hepcidin-25 (ln-hepcidin-25) was applied as the
dependent variable in all regression models since the distribution
of hepcidin-25 was positively skewed. The regression coefficients
(B) were retransformed into percentages of change in hepcidin-25
by using the formula (eB-1)6100, which means that for each
increment in the determinant, hepcidin-25 changed with the
specified percentage. Additionally, in a separate analysis, all
regression models were adjusted for participating center to correct
for local policies concerning anemia management and timing of
ESA and iron administration and blood withdrawal.
To evaluate whether the relation between a determinant (e.g.
hsCRP) and hepcidin-25 was modified by a second determinant
(e.g. ferritin), the possibility of effect modification was explored by
adding an interaction term (e.g. hsCRP x ferritin) to the
multivariable regression model. If this interaction term turned
out to be significant (p,0.05), the relation between the determi-
nant and hepcidin-25 was analyzed separately in each stratum of
the second determinant.
Statistical analyses were performed with PASW software
(version 18.0, SPSS inc. Headquarters, Chicago, Illinois, US).
Results
Blood samples from 405 patients were available. All patient and
treatment characteristics and laboratory parameters are listed in
table 1 (baseline characteristics of the total CONTRAST cohort
[n = 714] are listed in table S1). Mean (6 SD) age of the patients
was 63.7613.9 years and 62% was male. Hepcidin-20 and
hepcidin-25 were highly correlated (r = 0.76; p,0.001; figure 1).
In this section, results for hepcidin-25 are presented. In analyses
with hepcidin-20 as an outcome parameter, similar results were
obtained (data not shown).
Multivariable Regression Analysis
In table 2, all determinants of hepcidin showing a p-value
,0.15 in the backward multivariable linear regression model are
listed. In the final model (R2= 0.49), ferritin, hsCRP and the
presence of diabetes mellitus showed a positive relation with
hepcidin-25, whereas male gender, eGFR and sTfR had an
inverse relation. Of note, no relation between hepcidin-25 and the
weekly ESA dose and the administration of iron supplements was
observed. Adjustment for participating center did not change the
results (data not shown).
Interaction between Determinants
The relation between hsCRP and hepcidin-25 was modified by
the ferritin level, as the interaction term (hsCRP x ferritin) was
highly significant (p,0.001). This relation persisted after adjust-
ment for other determinants of hepcidin-25. As depicted in
figure 2, the relation between ferritin and hepcidin-25 was present
irrespective of the level of inflammation (lowest hsCRP tertile:
B = 0.020 per 10 ng/mL; 95%CI -0.015 to 0.026; p,0.001;
middle hsCRP tertile: B= 0.014 per 10 ng/mL; 95%CI 0.010 to
0.018; p,0.001; highest hsCRP tertile: B= 0.015 per 10 ng/mL;
95%CI 0.010 to 0.020; p,0.001). In fact, the relation between
hsCRP and hepcidin-25 was present in all three tertiles of ferritin
(lowest tertile: B = 0.020 per mg/L; 95%CI 20.010 to 0.030;
p,0.001; middle tertile: B = 0.009 per mg/L; 95%CI 0.000 to
0.018; p = 0.055; highest tertile: B= 0.007 per mg/L; 95%CI
0.001 to 0.013; p= 0.034).
No interaction between hemoglobin level and ESA dose on
hepcidin-25 levels was observed as the interaction term (ESA dose
X hemoglobin) was not statistically significant (p = 0.588). The
absence of a relation between those parameters is readily apparent
from figure 3.
Discussion
In this cross-sectional study in a cohort of stable prevalent HD
patients, hepcidin-25 levels were shown to be independently and
positively associated with iron stores (as reflected by ferritin levels),
inflammation (hsCRP) and the presence of diabetes, and inversely with
erythropoiesis (sTfR and reticulocyte count), residual kidney function
(eGFR) and male gender. Of note, no relations between hepcidin-25
and either ESA dose or iron supplementation were observed.
In our study, ferritin was the strongest determinant of hepcidin,
which has been well established before in healthy controls [29],
CKD patients [5,6,9,11] and in patients with ESRD treated with
HD and peritoneal dialysis [5,12,13,14,15]. Notably, the studies in
HD patients included mostly low patient numbers. As can be seen
from figure 2, the relation between hepcidin-25 and ferritin was
present irrespective of the level of inflammation. However,
whether hepcidin is upregulated in response to increased ferritin
levels cannot be concluded from our study.
sTfR has proven to be a valuable tool to assess bone marrow
erythropoietic activity and iron stores in HD patients treated with
ESA [30,31]. However, it could not predict a response of
intravenous iron administration on the hemoglobin level [32]. In
our study, an inverse association between either sTfR and
reticulocyte count, and hepcidin levels was observed, after
Figure 1. Correlation of Hepcidin-25 with its isoform hepcidin-
20. Hepcidin-20 and -25 were measured with mass spectrometry (WCX-
MALDI-TOF-MS, see section on laboratory protocol). r = 0.76; p-value
,0.001.
doi:10.1371/journal.pone.0039783.g001
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multivariable adjustments. Whether low hepcidin levels enhance
erythropoiesis, or whether increased bone marrow erythropoietic
activity suppresses expression of hepcidin, cannot be concluded
from this cross-sectional study.
We showed a strong association between hepcidin-25 and
hsCRP, but not with IL-6. Several studies have demonstrated a
relation between CRP [5,7,15,33] or IL-6 [7,13] in small groups of
chronic HD patients, whereas others did not [14]. The explana-
Table 2. Results from the multivariable regression analysis on hepcidin-25 levels.a
Multivariable regression
Determinant Bb 95% CIb % changec 95% CIc P-value
Gender (male) 20.188 20.361 to 20.016 217.1 230.3 to 21.6 0.032
Diabetes 0.246 0.034 to 0.458 27.9 3.5 to 58.1 0.023
Current smoker 20.188 20.390 to 0.014 217.1 232.3 to 1.4 0.067
Prescription of statins 20.162 20.332 to 0.009 215.0 228.3 to 0.9 0.063
Prescription of RAS inhibitors 0.113 20.056 to 0.282 12.0 25.4 to 28.7 0.053
eGFR (per mL/min/1.73 m2) 20.033 20.057 to 20.008 23.2 25.5 to 20.5 0.008
Hemoglobin (per g/dL) 0.085 0.019 to 0.152 8.9 1.9 to 16.4 0.012
MCV 20.011 20.025 to 0.004 21.1 22.5 to 0.4 0.150
Reticulocytes (per 10 *109/L) 20.034 20.063 to 20.006 23.3 26.1 to 20.6 0.019
Ferritin (per 10 ng/mL) 0.016 0.013 to 0.018 1.6 1.3 to 1.8 ,0.001
sTfR (per mg/L) 20.409 20.544 to 20.274 233.6 242.0 to 224.0 ,0.001
hsCRP (per mg/L) 0.012 0.007 to 0.017 1.2 0.7 to 1.4 ,0.001
aRegression analyses were performed with natural logarithm of hepcidin-25 as dependent variable. Potential determinants of hepcidin-25 were selected using a
backward multivariable linear regression model with a p-value ,0.15 used as a cut-off level in which all patient, treatment and laboratory characteristics as listed in
table 1 were entered.
bThe regression coefficient (B) denotes a natural logarithm. Positive values indicate an increase in hepcidin-25 and negative values a decrease with one unit increase of
the determinant.
cResults of conversion of the regression coefficient (B) from natural logarithm to a percentage of change: for each increase in the determinant with one unit, hepcidin-25
changed with the percentage indicated in this column. Positive values indicate an increase in hepcidin-25 and negative values a decrease.
R2 for multivariable regression model = 0.49. Further adjustment for participating center did not change the results (data not shown).
doi:10.1371/journal.pone.0039783.t002
Figure 2. Relationship between ferritin, hsCRP and hepcidin-25. Hepcidin-25 was ln-transformed because of a positively skewed distribution.
Values were adjusted for gender, diabetes, smoking status, prescription of statins and RAS inhibitors, eGFR, hemoglobin, MCV, absolute reticulocyte
count and the level of soluble transferrin receptor. CRP and ferritin levels were divided in tertiles. Numbers in boxes represent number of patients per
category. For 6 patients, ferritin and/or hsCRP levels were missing. P-value for interaction factor (hsCRP x ferritin) ,0.001.
doi:10.1371/journal.pone.0039783.g002
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tion for the association between hepcidin-25 and hsCRP, and not
IL-6, is not readily apparent, especially as transcription of hepatic
hepcidin is activated by binding of IL-6 to its receptor complex
[1]. However, in a murine and human model investigating various
factors associated with hepcidin expression, the role of IL-6 was
limited [34]. Furthermore, the IL-6 assay used in our study
showed a wide inter-assay variability, especially in the lower range.
This could have resulted in less accurately measured values of IL-6
as compared to hsCRP, and hence less precision in the estimation.
We are the first to report an independent association between
eGFR and both the active hepcidin-25 and the inactive isoform
hepcidin-20 in HD patients. As we used a mass-spectrometry assay
that specifically measures hepcidin-25, our results indicate that the
observed association between eGFR and hepcidin-25 was not due
to the concurrent measurement of inactive isoforms. To date,
studies on the association between eGFR and hepcidin levels in
CKD patients have been conflicting [5,6,11,35]. Low hepcidin
levels (measured with a radioimmunoassay) were reported in HD
and PD patients with residual diuresis [16], but RKF was not
quantified in that study. Whether the high hepcidin levels in
chronic HD patients were exclusively caused by decreased renal
clearance, or whether other mechanisms are involved, cannot be
concluded from our data.
In our study population, hepcidin-25 levels were significantly
lower in men as compared to women. This can be explained by
the fact that most women in our study will be post-menopausal, in
whom higher hepcidin levels have been demonstrated [29].
Furthermore, we showed that diabetic patients had higher
hepcidin levels. In one study, diabetic patients had higher levels
of hepcidin than healthy age-matched controls, although this
relation was not adjusted for possible confounders [36].
Interestingly, we did not observe an interaction between ESA
dose and hemoglobin levels in relation to hepcidin-25 as has been
demonstrated before by Ashby et al [11]. Therefore, it appears
that hepcidin, measured with a mass spectrometric assay in
chronic HD patients on maintenance therapy with ESA, is not a
marker of ESA resistance. Whether hepcidin-25 can predict an
ESA response, as has been shown in patients with the cardio-renal
syndrome [9], cannot be concluded from our cross-sectional data.
Nevertheless, in a study in 24 HD patients, hepcidin levels of ESA
responsive patients did not differ from those who were ESA
resistant [12], which is in accordance with our results.
Concerning iron supplementation in HD patients, various
effects of iron loading on hepcidin levels have been reported
[14,37,38]. We did not observe a relationship between hepcidin
and iron supplementation, which can be explained by the fact that
patients in our study received maintenance iron therapy instead of
a (single) loading dose. Recently, it was shown that hepcidin-25
levels did not predict a response to the administration of
intravenous iron supplementation in HD patients on ESA
maintenance therapy [38]. Hence, it appears that hepcidin is
more a marker of iron stores than a predictor of the effect of iron
therapy.
A number of studies showed that hepcidin levels could be
lowered over a single HD session [13,15,39], although concentra-
tions were back to baseline only one hour after the treatment [13].
Lowering of hepcidin by HD can be partly explained by
appearance of (low) levels of hepcidin in the ultrafiltrate [5,16].
In addition, it has been shown that hepcidin can attach to the
membrane of the dialyzer [5], which can be explained by the
amphipathic and protein-bound structure of hepcidin [2].
Prospective research is needed to draw any conclusions on the
effect of different dialyzers on hepcidin-levels.
Limitations and Strengths
Our study is limited by its cross-sectional design, which impedes
assessing causal relationships. Furthermore, a specific treatment
Figure 3. Relationship between ESA dose, hemoglobin and hepcidin-25. Hepcidin-25 was ln-transformed because of a positively skewed
distribution. Values were adjusted for gender, diabetes, smoking status, prescription of statins RAS inhibitors, eGFR, MCV, absolute reticulocyte count,
ferritin, hsCRP and soluble transferrin receptor. Only patients on ESA therapy are depicted (n = 364). Hemoglobin and ESA dose were divided in
tertiles. Numbers in boxes represent number of patients per category. P-value for interaction factor (ESA dose x hemoglobin) NS.
doi:10.1371/journal.pone.0039783.g003
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protocol for ESA and iron administration and timing of blood
sampling was not provided. We tried to compensate for this by
adjusting the regression models for participating center in an
additional analysis, as the intervals between ESA and/or iron
administration and blood sample withdrawal are supposed to be
similar within a single treatment center. Since this did not change
our results, we conclude that the dosing schedule was not a major
confounder in our study. Another potential limitation of our study
is the patient selection, based on centers where blood sampling and
storage was logistically feasible. This might have introduced a
selection bias of which the magnitude and direction cannot be
estimated. As selective participation or non-participation must
have occurred based on a logistical aspect, which is most probable
not related to factors associated with hepcidin or determinants of
hepcidin, selection bias seems unlikely.
The strength of our study is the large sample size and the
prospective data collection. As far as we know, our study comprises
the largest cohort of HD patients in which hepcidin measurements
were performed, currently published. The large sample size
facilitates multivariable statistics, which is an important method
when examining the complex regulation of hepcidin [40].
Moreover, hepcidin measurements have been performed with a
validated mass spectrometric technique, enabling specific quanti-
fication of the bioactive hepcidin-25.
Conclusions
In this cohort of chronic, stable HD patients, hepcidin-25 levels
were independently associated with iron stores (as reflected by
ferritin levels), erythropoiesis (reticulocyte count and sTfR),
inflammation (hsCRP), eGFR, the presence of diabetes and
gender. Hepcidin-25 was strongly correlated with its bio-inactive
isoform hepcidin-20, and similar associations with hepcidin-20
were identified. Of note, hepcidin-25 was not associated with the
maintenance dose of ESA or iron therapy.
Our findings confirm the role of hepcidin as a biomarker of iron
stores and erythropoiesis in chronic HD patients and indicate that
hepcidin is not a biomarker of ESA resistance in patients on ESA
maintenance therapy. Furthermore, it underscores the potential
important role of (limited) RKF in HD patients. However,
whether low hepcidin levels in HD patients are associated with a
favorable outcome in terms of morbidity and mortality is not clear
yet. Furthermore, whether hepcidin measurements in HD patients
provide additional information concerning anemia management
compared to current available markers such as ferritin is
questionable.
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